|
|
Rucaparib is a breakthrough in precision medicine, particularly for patients with advanced ovarian and prostate cancers. As a poly(ADP-ribose) polymerase (PARP) inhibitor, Rucaparib targets cancer cells with BRCA1 or BRCA2 gene mutations, which are involved in DNA repair. By inhibiting the PARP enzyme, Rucaparib prevents cancer cells from repairing their DNA, leading to cell death, while sparing healthy cells. This makes it a highly targeted treatment option with fewer side effects compared to conventional chemotherapy.
The drug's ability to work effectively on specific genetic mutations has made it a game-changer in oncology, offering patients a personalized treatment approach that improves survival rates and quality of life. As precision medicine continues to evolve, Rucaparib's role is expected to grow, making it an essential option in cancer care.
Rucaparib manufacturers in India are at the forefront of making this cutting-edge treatment accessible globally. These manufacturers adhere to stringent quality standards, ensuring the drug is produced under Good Manufacturing Practices (GMP). By supplying Rucaparib to healthcare systems worldwide, they contribute to expanding access to innovative treatments, ensuring that more patients benefit from precision therapies in the fight against cancer.
|
|
發表於